Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 356 articles:
HTML format



Single Articles


    August 2021
  1. YAMADA M, Kubo M, Yamamoto H, Yamashita N, et al
    Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.
    Anticancer Res. 2021;41:4143-4149.
    PubMed     Abstract available


  2. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy.
    Anticancer Res. 2021;41:4133-4141.
    PubMed     Abstract available


  3. OGINO M, Fujii T, Koibuchi Y, Nakazawa Y, et al
    Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer.
    Anticancer Res. 2021;41:3899-3904.
    PubMed     Abstract available


  4. STELLER D, Simon R, VON Bialy R, Hakim SG, et al
    Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
    Anticancer Res. 2021;41:3917-3923.
    PubMed     Abstract available


  5. KIM H, Gim JA, Kim CY, Kim A, et al
    Intratumor Heterogeneity of Synchronous In Situ and Invasive Breast Carcinoma Revealed Using Multi-region Exome Sequencing.
    Anticancer Res. 2021;41:3779-3787.
    PubMed     Abstract available


    July 2021
  6. YAMANOUCHI K, Maeda S, Takei D, Koga Y, et al
    Pretreatment Absolute Lymphocyte Count and Neutrophil-to-lymphocyte Ratio Are Prognostic Factors for Stage III Breast Cancer.
    Anticancer Res. 2021;41:3625-3634.
    PubMed     Abstract available


  7. TANG A, Mooney CM, Beattie G, Cohan CM, et al
    Health Equity Within Inequity: Timing of Diagnostic Breast Cancer Care in an Underserved Medical Population.
    Anticancer Res. 2021;41:3607-3613.
    PubMed     Abstract available


  8. SUZUKI C, Yamada A, Adachi S, Shima H, et al
    Bromodomain-containing Protein 4 Is a Favourable Prognostic Factor in Breast Cancer Patients.
    Anticancer Res. 2021;41:3597-3606.
    PubMed     Abstract available


  9. RAJBONGSHI L, Noh MH, Kim YS, Hur DY, et al
    Effects of Epstein-Barr Virus Infection on the Response of Human Breast Cancer Cells to Nicotine.
    Anticancer Res. 2021;41:3449-3458.
    PubMed     Abstract available


  10. VIEIRA JF, Peixoto AP, Murta EFC, Michelin MA, et al
    Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases.
    Anticancer Res. 2021;41:3419-3427.
    PubMed     Abstract available


  11. KIM CY, Kim YC, Oh JH, Kim MH, et al
    HOXB5 Confers Tamoxifen Resistance in Breast Cancer Cells and Promotes Tumor Aggression and Progression.
    Anticancer Res. 2021;41:3409-3417.
    PubMed     Abstract available


  12. MARCHICA P, D'Arpa S, Magno S, Rossi C, et al
    Integrated Treatment of Breast Cancer-related Lymphedema: A Descriptive Review of the State of the Art.
    Anticancer Res. 2021;41:3233-3246.
    PubMed     Abstract available


    June 2021
  13. KIM K, Chun M, Jin H, Jung W, et al
    Inter-institutional Variation in Intensity-modulated Radiotherapy for Breast Cancer in Korea (KROG 19-01).
    Anticancer Res. 2021;41:3145-3152.
    PubMed     Abstract available


  14. AKAGI H, Shimada A, Chin K, Domoto H, et al
    Successful Stabilization of Symptomatic Bone Marrow Metastasis Two Times in a Breast Cancer Patient.
    Anticancer Res. 2021;41:3139-3144.
    PubMed     Abstract available


  15. MIKI M, Takao S, Konishi M, Shigeoka Y, et al
    Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
    Anticancer Res. 2021;41:3121-3126.
    PubMed     Abstract available


  16. KRAWCZYK N, Janowski K, Banys-Paluchowski M, Staebler A, et al
    The SOX2 Status of Disseminated Tumor Cells in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Anticancer Res. 2021;41:2849-2858.
    PubMed     Abstract available


  17. WALL TP, Crowley PD, Buggy DJ
    The Effect of Lidocaine and Bosutinib on 4T1 Murine Breast Cancer Cell Behaviour In Vitro.
    Anticancer Res. 2021;41:2835-2840.
    PubMed     Abstract available


  18. OHLINGER R, Alwafai Z, Paepke S, Zygmunt M, et al
    Patient Quality of Life After Subpectoral Implant-based Breast Reconstruction With Synthetic or Biological Materials.
    Anticancer Res. 2021;41:3075-3082.
    PubMed     Abstract available


    May 2021
  19. ORSARIA P, Grasso A, Ippolito E, Pantano F, et al
    Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
    Anticancer Res. 2021;41:2697-2709.
    PubMed     Abstract available


  20. VANNI G, Pellicciaro M, Materazzo M, Pedini D, et al
    Advanced Stages and Increased Need for Adjuvant Treatments in Breast Cancer Patients: The Effect of the One-year COVID-19 Pandemic.
    Anticancer Res. 2021;41:2689-2696.
    PubMed     Abstract available


  21. RADES D, Narvaez CA, Dziggel L, Tvilsted S, et al
    Sleep Disorders in Patients With Breast Cancer Prior to a Course of Radiotherapy - Prevalence and Risk Factors.
    Anticancer Res. 2021;41:2489-2494.
    PubMed     Abstract available


  22. CHEN KY, Chien WC, Liao JM, Tsai CW, et al
    Contribution of Interleukin-10 Genotype to Triple Negative Breast Cancer Risk.
    Anticancer Res. 2021;41:2451-2457.
    PubMed     Abstract available


  23. ALAAELDIN R, Abuo-Rahma GEA, Zhao QL, Fathy M, et al
    Modulation of Apoptosis and Epithelial-Mesenchymal Transition E-cadherin/TGF-beta/Snail/TWIST Pathways by a New Ciprofloxacin Chalcone in Breast Cancer Cells.
    Anticancer Res. 2021;41:2383-2395.
    PubMed     Abstract available


  24. JINIH M, Wang JH, Pfirrmann RW, O'Leary DP, et al
    Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells.
    Anticancer Res. 2021;41:2247-2256.
    PubMed     Abstract available


  25. GUSHO CA, Blank AT
    What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?
    Anticancer Res. 2021;41:2473-2476.
    PubMed     Abstract available


    April 2021
  26. HAYASHI K, Tamura M, Nagasaki E, Yoshii Y, et al
    A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer.
    Anticancer Res. 2021;41:2193-2195.
    PubMed     Abstract available


  27. SASAKI R, Horimoto Y, Yanai Y, Kurisaki-Arakawa A, et al
    Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:2133-2140.
    PubMed     Abstract available


  28. VANNI G, Materazzo M, Pellicciaro M, Amir S, et al
    Breast Textured Implants Determine Early T-helper Impairment: BIAL2.20 Study.
    Anticancer Res. 2021;41:2123-2132.
    PubMed     Abstract available


  29. JOSEPH WJ, Bustos SS, Losee JE, Rubin JP, et al
    The Impact of the COVID-19 Pandemic on Breast Reconstruction Practices in the United States.
    Anticancer Res. 2021;41:1903-1908.
    PubMed     Abstract available


  30. RIGAKOS G, Razis E, Koliou GA, Oikonomopoulos G, et al
    Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
    Anticancer Res. 2021;41:1793-1802.
    PubMed     Abstract available


  31. OHLINGER R, Nawroth F, Kohlmann T, Alwafai Z, et al
    Retrospective Study of Radiotherapy Impact on the Outcome of Material-assisted Implant-based Subpectoral Breast Reconstruction.
    Anticancer Res. 2021;41:2017-2024.
    PubMed     Abstract available


  32. ZWICKER F, Hoefel S, Kirchner C, Huber PE, et al
    Hypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge.
    Anticancer Res. 2021;41:1909-1920.
    PubMed     Abstract available


    March 2021
  33. YAMAMOTO S, Narui K, Ishikawa T, Adachi S, et al
    First-line Gemcitabine Versus Treatment of Physician's Choice for Metastatic Breast Cancer: A Prospective Cohort Study.
    Anticancer Res. 2021;41:1671-1676.
    PubMed     Abstract available


  34. FERINI G, Molino L, Tripoli A, Valenti V, et al
    Anatomical Predictors of Dosimetric Advantages for Deep-inspiration-breath-hold 3D-conformal Radiotherapy Among Women With Left Breast Cancer.
    Anticancer Res. 2021;41:1529-1538.
    PubMed     Abstract available


  35. KRAJNAK S, Loewe A, Battista MJ, Hasenburg A, et al
    The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells.
    Anticancer Res. 2021;41:1243-1250.
    PubMed     Abstract available


  36. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available


    February 2021
  37. INOUE S, Kawaida H, Saito R, Nakayama Y, et al
    Clinical Significance of Past History of Breast Cancer Screening for the Prognosis of Triple Negative Breast Cancer.
    Anticancer Res. 2021;41:1077-1082.
    PubMed     Abstract available


  38. YAMADA A, Nakazawa K, Akazawa K, Narui K, et al
    Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study.
    Anticancer Res. 2021;41:1063-1068.
    PubMed     Abstract available


  39. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Elevated Free Triiodothyronine Is Associated With Increased Proliferative Activity in Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:949-954.
    PubMed     Abstract available


  40. OKAZAKI M, Mogushi K, Denda-Nagai K, Fujihira H, et al
    Biological and Clinicopathological Implications of Beta-3-N-acetylglucosaminyltransferase 8 in Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:845-858.
    PubMed     Abstract available


  41. RAICA M, Ceausu AR, Cimpean AM, ComSa S, et al
    Chloride Intracellular Channel Protein 1 (CLIC1), E-cadherin and P-cadherin Define Distinct Subclasses of HER2, Luminal B and Triple-negative Breast Cancer.
    Anticancer Res. 2021;41:795-802.
    PubMed     Abstract available


  42. SHARIF-ASKARI FS, Al-Khayyal N, Talaat I, Sharif-Askari NS, et al
    Immunohistochemical Assessment of TNFAIP3/A20 Expression Correlates With Early Tumorigenesis in Breast Cancer.
    Anticancer Res. 2021;41:739-745.
    PubMed     Abstract available


  43. PAPADAKI MA, Aggouraki D, Vetsika EK, Xenidis N, et al
    Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Anticancer Res. 2021;41:661-670.
    PubMed     Abstract available


  44. UNGER J, Rutkowski R, Kohlmann T, Paepke S, et al
    Potential Risk Factors Influencing the Formation of Postoperative Seroma After Breast Surgery - A Prospective Study.
    Anticancer Res. 2021;41:859-867.
    PubMed     Abstract available


  45. WALKER RR, Gallegos KM, Bratton MR, Lemieux KP, et al
    Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade.
    Anticancer Res. 2021;41:583-599.
    PubMed     Abstract available


    January 2021
  46. SCHMIDT M, KUmmel S, Ruf-Doerdelmann A, Distelrath A, et al
    Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin((R))) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin).
    Anticancer Res. 2021;41:485-496.
    PubMed     Abstract available


  47. OBA T, Maeno K, Ono M, Ito T, et al
    Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
    Anticancer Res. 2021;41:445-452.
    PubMed     Abstract available


  48. SAGARA M, Miyamoto S, Itoh S, Soda Y, et al
    Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
    Anticancer Res. 2021;41:81-89.
    PubMed     Abstract available


  49. CHOI YE, Sung K, Dong KS, Kim HJ, et al
    Dosimetric Impact of Respiratory Motion During Breast Intensity-modulated Radiation Therapy Using Four-dimensional Dose Calculations.
    Anticancer Res. 2021;41:417-427.
    PubMed     Abstract available


  50. IBRAGIMOVA MK, Tsyganov MM, Pevzner AM, Litviakov NV, et al
    Transcriptome of Breast Tumors With Different Amplification Status of the Long Arm of Chromosome 8.
    Anticancer Res. 2021;41:187-195.
    PubMed     Abstract available


  51. ONAGA C, Tamori S, Motomura H, Ozaki A, et al
    High SLC20A1 Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers.
    Anticancer Res. 2021;41:43-54.
    PubMed     Abstract available


    December 2020
  52. VANNI G, Tazzioli G, Pellicciaro M, Materazzo M, et al
    Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients.
    Anticancer Res. 2020;40:7119-7125.
    PubMed     Abstract available


  53. MACAIONE I, Galvano A, Graceffa G, Lupo S, et al
    Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer.
    Anticancer Res. 2020;40:7083-7088.
    PubMed     Abstract available


  54. TSAI CL, Tsai CW, Chang WS, Su CH, et al
    Interleukin-13 Promoter Genotypes and Taiwanese Breast Cancer Susceptibility.
    Anticancer Res. 2020;40:6743-6749.
    PubMed     Abstract available


  55. YAMADA A, Suzuki C, Shima H, Kida K, et al
    Aldehyde Dehydrogenase 1-related Genes in Triple-negative Breast Cancer Investigated Using Network Analysis.
    Anticancer Res. 2020;40:6733-6742.
    PubMed     Abstract available


  56. NIWA Y, Asano M, Nakagawa T, France D, et al
    Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
    Anticancer Res. 2020;40:6699-6712.
    PubMed     Abstract available


  57. ANAYA-EUGENIO GD, Eggers NA, Ren Y, Rivera-ChAvez J, et al
    Apoptosis Induced by (+)-Betulin Through NF-kappaB Inhibition in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2020;40:6637-6647.
    PubMed     Abstract available


  58. ROBINSON AGJ, Kanaan YM, Copeland RL
    Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2020;40:6623-6635.
    PubMed     Abstract available


    November 2020
  59. NUZZO M, Ursini LA, Patani F, Rosa C, et al
    Using the Bolus in Post-mastectomy Radiation Therapy (PMRT): A National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Breast Cancer Group.
    Anticancer Res. 2020;40:6505-6511.
    PubMed     Abstract available


  60. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
    Anticancer Res. 2020;40:6417-6428.
    PubMed     Abstract available


  61. AUGUSTINE TN, Duarte R, Candy GP
    Breast Cancer Cells Induce a Pro-inflammatory Response to Mitigate Immune Mediation in a 3D Culture Model.
    Anticancer Res. 2020;40:6179-6193.
    PubMed     Abstract available


  62. SHIMODA M, Kim SJ, Tokuda Y, Sota Y, et al
    Effect of Computer-aided Detection System Use on the Duration of MRI-guided Biopsy of the Breast.
    Anticancer Res. 2020;40:6437-6441.
    PubMed     Abstract available


  63. STOPE MB, Benouahi R, Sander C, Haralambiev L, et al
    Protherapeutic Effects and Inactivation of Mammary Carcinoma Cells by a Medical Argon Plasma Device.
    Anticancer Res. 2020;40:6205-6212.
    PubMed     Abstract available


    October 2020
  64. SHINDEN Y, Nagata A, Nomoto Y, Saho H, et al
    Surgical Resection With Pedicled Rotation Flap for Post-mastectomy Locoregional Breast Cancer Recurrence.
    Anticancer Res. 2020;40:5739-5742.
    PubMed     Abstract available


  65. YENILMEZ EN, Genc D, Farooqi AA, Tunoglu S, et al
    Mesenchymal Stem Cells Combined With IFNgamma Induce Apoptosis of Breast Cancer Cells Partially Through TRAIL.
    Anticancer Res. 2020;40:5641-5647.
    PubMed     Abstract available


  66. MARGAN MM, Cimpean AM, Ceausu AR, Raica M, et al
    Differential Expression of E-Cadherin and P-Cadherin in Breast Cancer Molecular Subtypes.
    Anticancer Res. 2020;40:5557-5566.
    PubMed     Abstract available


  67. LI CL, Huang CW, Ko CJ, Fang SY, et al
    Curcumol Suppresses Triple-negative Breast Cancer Metastasis by Attenuating Anoikis Resistance via Inhibition of Skp2-mediated Transcriptional Addiction.
    Anticancer Res. 2020;40:5529-5538.
    PubMed     Abstract available


  68. SCATOZZA F, D'Amore A, Fontanella RA, DE Cesaris P, et al
    Toll-Iike Receptor-3 Activation Enhances Malignant Traits in Human Breast Cancer Cells Through Hypoxia-inducible Factor-1alpha.
    Anticancer Res. 2020;40:5379-5391.
    PubMed     Abstract available


  69. WAZIR U, Mokbel K
    De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe?
    Anticancer Res. 2020;40:5351-5354.
    PubMed     Abstract available


  70. KIM SW, Kim HS, Na K
    Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma.
    Anticancer Res. 2020;40:5925-5932.
    PubMed     Abstract available


  71. PARK JH, Ahn JH, Kim JE, Jung KH, et al
    Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Anticancer Res. 2020;40:5883-5893.
    PubMed     Abstract available


  72. YILDIRIM E, Bektas S, Gundogar O, Findik D, et al
    The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
    Anticancer Res. 2020;40:5649-5657.
    PubMed     Abstract available


  73. PERNICONE N, Peretz L, Grinshpon S, Listovsky T, et al
    MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis.
    Anticancer Res. 2020;40:5471-5480.
    PubMed     Abstract available


    September 2020
  74. MINAMI H, Ando Y, Tamura K, Tajima T, et al
    Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:5229-5235.
    PubMed     Abstract available


  75. LEE HS, Oh DS
    Assessing the Anti-cancer Therapeutic Mechanism of a Herbal Combination for Breast Cancer on System-level by a Network Pharmacological Approach.
    Anticancer Res. 2020;40:5097-5106.
    PubMed     Abstract available


  76. BHATTARAI PY, Oh CH, Kim G, Kim MS, et al
    Novel Imidazo[2,1-b]oxazole Derivatives Inhibit Epithelial Cell Transformation and Triple Negative Breast Cancer Tumorigenesis.
    Anticancer Res. 2020;40:5081-5090.
    PubMed     Abstract available


  77. SUGISAWA N, Hamada K, Han Q, Yamamoto J, et al
    Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
    Anticancer Res. 2020;40:4869-4874.
    PubMed     Abstract available


  78. STRAVODIMOU A, Voutsadakis IA
    The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
    Anticancer Res. 2020;40:4829-4841.
    PubMed     Abstract available


  79. NASIR UM, Mozeika AM, Sayan M, Jan I, et al
    Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.
    Anticancer Res. 2020;40:5291-5294.
    PubMed     Abstract available


    August 2020
  80. TANAKA T, Tanaka M, Furusawa H, Kamada Y, et al
    Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer.
    Anticancer Res. 2020;40:4779-4785.
    PubMed     Abstract available


  81. KAMIO T, Kamio H, Aoki T, Ondo Y, et al
    Molecular Profiles of Breast Cancer in a Single Institution.
    Anticancer Res. 2020;40:4567-4570.
    PubMed     Abstract available


  82. SUKJOI W, Siritutsoontorn S, Chansongkrow P, Waiwitlikhit S, et al
    Overexpression of Holocarboxylase Synthetase Predicts Lymph Node Metastasis and Unfavorable Prognosis in Breast Cancer.
    Anticancer Res. 2020;40:4557-4565.
    PubMed     Abstract available


  83. KIM TH, Kwon SC, Kim JN, Yoon JH, et al
    Ginseng Seed Oil Inhibits the Growth of Estrogen Receptor-positive Breast Cancer Cells.
    Anticancer Res. 2020;40:4529-4535.
    PubMed     Abstract available


  84. ISHIZUKA Y, Horimoto Y, Nakamura M, Arakawa A, et al
    Predictive Factors for Non-sentinel Nodal Metastasis in Patients With Sentinel Lymph Node-positive Breast Cancer.
    Anticancer Res. 2020;40:4405-4412.
    PubMed     Abstract available


  85. MARECHAL S, Graas MP, Collard L, Collin M, et al
    Interest for a Systematic Rehabilitation Program Including Physical Exercise and Lifestyle Accompaniment for Women Recently Treated for Early Breast Cancer: A Comparative Study.
    Anticancer Res. 2020;40:4253-4261.
    PubMed     Abstract available


    July 2020
  86. HANKER LC, FOrster F, SchrOder J, Grafe A, et al
    Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer.
    Anticancer Res. 2020;40:3973-3981.
    PubMed     Abstract available


  87. TAKEUCHI H, Noda D, Abe M, Anami K, et al
    Evaluating the Platelet Distribution Width-to-Plateletcrit Ratio as a Prognostic Marker for Patients With Breast Cancer.
    Anticancer Res. 2020;40:3947-3952.
    PubMed     Abstract available


  88. HEUDEL P, Delaloge S, Parent D, Madranges N, et al
    Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
    Anticancer Res. 2020;40:3905-3913.
    PubMed     Abstract available


  89. MASUDA T, Noda M, Kitagawa A, Hu Q, et al
    The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer.
    Anticancer Res. 2020;40:3733-3742.
    PubMed     Abstract available


  90. NOURIEMAMZADEN F, Word B, Cotton E, Hawkins A, et al
    Modulation of Estrogen alpha and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
    Anticancer Res. 2020;40:3669-3683.
    PubMed     Abstract available


  91. SUSINI T, Renda I
    FGD3 Gene as a New Prognostic Factor in Breast Cancer.
    Anticancer Res. 2020;40:3645-3649.
    PubMed     Abstract available


  92. DOFARA SG, Chang SL, Diorio C
    Gene Polymorphisms and Circulating Levels of MMP-2 and MMP-9: A Review of Their Role in Breast Cancer Risk.
    Anticancer Res. 2020;40:3619-3631.
    PubMed     Abstract available


  93. SATA A, Fukui R, Miyagawa Y, Bun A, et al
    C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
    Anticancer Res. 2020;40:4147-4156.
    PubMed     Abstract available


  94. TAKAHASHI M, Takahashi K, Matsumoto S, Takashima T, et al
    Low Eosinophil Percentages as a New Predictive Marker for Infusion Reactions Due to Trastuzumab.
    Anticancer Res. 2020;40:4047-4051.
    PubMed     Abstract available


  95. KASEM I, Mokbel K
    Savi Scout(R) Radar Localisation of Non-palpable Breast Lesions: Systematic Review and Pooled Analysis of 842 Cases.
    Anticancer Res. 2020;40:3633-3643.
    PubMed     Abstract available


  96. TAYEH S, Muktar S, Heeney J, Michell MJ, et al
    Reflector-guided Localization of Non-palpable Breast Lesions: The First Reported European Evaluation of the SAVI SCOUT(R) System.
    Anticancer Res. 2020;40:3915-3924.
    PubMed     Abstract available


  97. COHEN-HARAZI R, Hofmann S, Kogan V, Fulman-Levy H, et al
    Cytotoxicity of Exogenous Acetoacetate in Lithium Salt Form Is Mediated by Lithium and Not Acetoacetate.
    Anticancer Res. 2020;40:3831-3837.
    PubMed     Abstract available


    June 2020
  98. FREGATTI P, Gipponi M, Zoppoli G, Lambertini M, et al
    Tumor-to-nipple Distance Should Not Preclude Nipple-sparing Mastectomy in Breast Cancer Patients. Personal Experience and Literature Review.
    Anticancer Res. 2020;40:3543-3550.
    PubMed     Abstract available


  99. SASADA S, Masumoto N, Kimura Y, Emi A, et al
    Classification of Abnormal Findings on Ring-type Dedicated Breast PET for the Detection of Breast Cancer.
    Anticancer Res. 2020;40:3491-3497.
    PubMed     Abstract available


  100. SASADA S, Kimura Y, Emi A, Masumoto N, et al
    Tumor-infiltrating Lymphocyte Score Based on FDG PET/CT for Predicting the Effect of Neoadjuvant Chemotherapy in Breast Cancer.
    Anticancer Res. 2020;40:3395-3400.
    PubMed     Abstract available


  101. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer.
    Anticancer Res. 2020;40:3345-3354.
    PubMed     Abstract available


  102. OKAMOTO M, Tajiri W, Ueo H, Masuda T, et al
    Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice.
    Anticancer Res. 2020;40:3315-3323.
    PubMed     Abstract available


  103. DABROWSKA E, Przylipiak A, Zajkowska M, Piskor BM, et al
    Possible Diagnostic Application of CXCL12 and CXCR4 as Tumor Markers in Breast Cancer Patients.
    Anticancer Res. 2020;40:3221-3229.
    PubMed     Abstract available


  104. INUBUSHI S, Kawaguchi H, Mizumoto S, Kunihisa T, et al
    Oncogenic miRNAs Identified in Tear Exosomes From Metastatic Breast Cancer Patients.
    Anticancer Res. 2020;40:3091-3096.
    PubMed     Abstract available


  105. SCHMIDT-WOLF R, Zissel G
    Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30.
    Anticancer Res. 2020;40:3097-3108.
    PubMed     Abstract available


  106. TUNG KL, Wu YT, Liu C, Lin SC, et al
    EBV Rta-induced IL-6 Promotes Migration of Bystander Tumor Cells Through IL-6R/JAK/STAT3 Pathway In Vitro.
    Anticancer Res. 2020;40:3255-3264.
    PubMed     Abstract available


    May 2020
  107. DA SILVA A, Levy C, Allouache D, Hrab I, et al
    Efficacy and Safety of Weekly Paclitaxel in Breast Cancer With Symptomatic Bone Marrow Infiltration.
    Anticancer Res. 2020;40:2955-2960.
    PubMed     Abstract available


  108. JUN S, Kim SW, Lim JY, Park SJ, et al
    ABHD12 Knockdown Suppresses Breast Cancer Cell Proliferation, Migration and Invasion.
    Anticancer Res. 2020;40:2601-2611.
    PubMed     Abstract available


  109. WATROWSKI R, Castillo-Tong DC, Obermayr E, Zeillinger R, et al
    Gene Expression of Kallikreins in Breast Cancer Cell Lines.
    Anticancer Res. 2020;40:2487-2495.
    PubMed     Abstract available


  110. LIM HI, Yamamoto J, Inubushi S, Nishino H, et al
    A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
    Anticancer Res. 2020;40:2481-2485.
    PubMed     Abstract available


  111. YAMAMOTO J, Murata T, Tashiro Y, Higuchi T, et al
    A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
    Anticancer Res. 2020;40:2509-2514.
    PubMed     Abstract available


  112. YAMAMOTO J, Murata T, Sugisawa N, Higuchi T, et al
    Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
    Anticancer Res. 2020;40:2475-2479.
    PubMed     Abstract available


  113. GKANTAIFI A, Papadopoulos C, Spyropoulou D, Toumpourleka M, et al
    Evaluation of the Irradiated Volume of the Heart and Cardiac Substructures After Left Breast Radiotherapy.
    Anticancer Res. 2020;40:3003-3009.
    PubMed     Abstract available


  114. PARK S, Cho EY, Oh YL, Park YH, et al
    Primary Peritoneal High-grade Serous Carcinoma Misinterpreted as Metastatic Breast Carcinoma: A Rare Encounter in Peritoneal Fluid Cytology.
    Anticancer Res. 2020;40:2933-2939.
    PubMed     Abstract available


  115. BUN A, Fujimoto Y, Higuchi T, Sata A, et al
    Prognostic Significance of Neutrophil-to-lymphocyte Ratio in Luminal Breast Cancers With Low Levels of Tumour-infiltrating Lymphocytes.
    Anticancer Res. 2020;40:2871-2880.
    PubMed     Abstract available


    April 2020
  116. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Prediction of Sentinel Lymph Node Metastasis Using the Platelet-to-lymphocyte Ratio in T1 Breast Cancer.
    Anticancer Res. 2020;40:2343-2349.
    PubMed     Abstract available


  117. KUBA S, Maeda S, Matsumoto M, Yamanouchi K, et al
    Optimal Tumor Reduction Rate and Modalities for Predicting pCR in Women With Breast Cancer.
    Anticancer Res. 2020;40:2303-2309.
    PubMed     Abstract available


  118. GRASSO A, Orsaria P, Costa F, D'Avino V, et al
    Ultrasound-guided Interfascial Plane Blocks for Non-anesthesiologists in Breast Cancer Surgery: Functional Outcomes and Benefits.
    Anticancer Res. 2020;40:2231-2238.
    PubMed     Abstract available


  119. DAVEY S, Roche A, Pegba-Otemolu I, Ibrahim A, et al
    Comparison of Patient Satisfaction on a Day-case Mastectomy Pathway for Breast Cancer Versus a Traditional Inpatient Delivery Model, Using a Validated Questionnaire.
    Anticancer Res. 2020;40:2179-2183.
    PubMed     Abstract available


  120. FUKUI R, Fujimoto Y, Watanabe T, Inoue N, et al
    Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes.
    Anticancer Res. 2020;40:2141-2150.
    PubMed     Abstract available


  121. MULLER M, Guth U, Varga Z, Reeve K, et al
    Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer.
    Anticancer Res. 2020;40:2125-2131.
    PubMed     Abstract available


  122. PARK SY, Lee JK, Park MH, Jeong KY, et al
    Potential Anticancer Effect of Calcium-mediated Src Degradation on Hormone-dependent Breast Cancer.
    Anticancer Res. 2020;40:1989-1996.
    PubMed     Abstract available


  123. LIM JY, Kim SW, Kim B, Park SJ, et al
    Knockdown of CARD14 Inhibits Cell Proliferation and Migration in Breast Cancer Cells.
    Anticancer Res. 2020;40:1953-1962.
    PubMed     Abstract available


  124. VEENA V, Harikrishnan A, Lakshmi B, Khanna S, et al
    A New Model Applied for Evaluating a Rhenium-diselenium Drug: Breast Cancer Cells Stimulated by Cytokines Induced from Polynuclear Cells by LPS.
    Anticancer Res. 2020;40:1915-1920.
    PubMed     Abstract available


  125. LEE H, Lee M, Seo JH, Gong G, et al
    Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer.
    Anticancer Res. 2020;40:1883-1890.
    PubMed     Abstract available


  126. NAKAYAMA H, Kawachi K, Suganuma N, Yoshida T, et al
    EZH2 and MMSET Were Identified as Potentially Useful Therapeutic Targets in Metaplastic Breast Carcinoma.
    Anticancer Res. 2020;40:2133-2139.
    PubMed     Abstract available


  127. GERA R, Tayeh S, Al-Reefy S, Mokbel K, et al
    Evolving Role of Magseed in Wireless Localization of Breast Lesions: Systematic Review and Pooled Analysis of 1,559 Procedures.
    Anticancer Res. 2020;40:1809-1815.
    PubMed     Abstract available


  128. DRAGIC D, Ennour-Idrissi K, Michaud A, Chang SL, et al
    Association Between BMI and DNA Methylation in Blood or Normal Adult Breast Tissue: A Systematic Review.
    Anticancer Res. 2020;40:1797-1808.
    PubMed     Abstract available


  129. RADES D, Nguyen T, Janssen S, Khoa MT, et al
    Individualisation of Radiation Therapy for Older Persons With Secondary Brain Lesions from Carcinoma of the Breast.
    Anticancer Res. 2020;40:2271-2274.
    PubMed     Abstract available


  130. OHLINGER R, Flieger C, Hahndorf W, Paepke S, et al
    Correlation of Ductoscopic and Histopathological Findings and Their Relevance as Predictors for Malignancy: A German Multicenter Study.
    Anticancer Res. 2020;40:2185-2190.
    PubMed     Abstract available


    March 2020
  131. ARKOSY P, Toth J, Beres E, Toth D, et al
    Prognosis and Treatment Outcomes of Patients Undergoing Resection of Brain Metastases from Breast Cancer.
    Anticancer Res. 2020;40:1759-1770.
    PubMed     Abstract available


  132. CIPOLLA C, Graceffa G, Cabibi D, Gangi G, et al
    Current Role of Intraoperative Frozen Section Examination of Sentinel Lymph Node in Early Breast Cancer.
    Anticancer Res. 2020;40:1711-1717.
    PubMed     Abstract available


  133. ALKHAYYAL N, Talaat I, Vinodnadat A, Maghazachi A, et al
    Correlation of Insulin-like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast Cancer in the UAE.
    Anticancer Res. 2020;40:1555-1561.
    PubMed     Abstract available


  134. HONG SE, Kim MR, Jang SK, Seong MK, et al
    Hypoxia Suppresses Cysteine Deprivation-induced Cell Death Via ATF4 Regulation in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2020;40:1387-1394.
    PubMed     Abstract available


  135. GKRETSI V, Stylianou A, Kalli M, Louca M, et al
    Silencing of Growth Differentiation Factor-15 Promotes Breast Cancer Cell Invasion by Down-regulating Focal Adhesion Genes.
    Anticancer Res. 2020;40:1375-1385.
    PubMed     Abstract available


  136. KIM HS, DO SI, Kim DH, Apple S, et al
    Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma.
    Anticancer Res. 2020;40:1487-1494.
    PubMed     Abstract available


  137. PERRETTA T, Lamacchia F, Ferrari D, Beninati E, et al
    Evaluation of Ultrasound-guided 8-Gauge Vacuum-assisted Excision System for the Removal of US-detectable Breast Lesions.
    Anticancer Res. 2020;40:1719-1729.
    PubMed     Abstract available


    February 2020
  138. GIANI M, Renda I, Vallario A, Tavella K, et al
    Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience.
    Anticancer Res. 2020;40:1079-1085.
    PubMed     Abstract available


  139. MORAIS S, Costa AR, Lopes-Conceicao L, Brandao M, et al
    Treatment and Other Healthcare Use of Breast Cancer Patients With a Previous Cancer Diagnosis.
    Anticancer Res. 2020;40:1041-1048.
    PubMed     Abstract available


  140. PHILIPOVSKIY A, Campbell A, Heydarian R, Castillo B, et al
    Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer.
    Anticancer Res. 2020;40:857-864.
    PubMed     Abstract available


  141. KLOPOTOWSKA D, Matuszyk J
    VDR Agonists Increase Sensitivity of MCF-7 and BT-474 Breast Cancer Cells to 5 FU.
    Anticancer Res. 2020;40:837-840.
    PubMed     Abstract available


  142. RAD JG, Hoskin DW
    Delivery of Apoptosis-inducing Piperine to Triple-negative Breast Cancer Cells via Co-polymeric Nanoparticles.
    Anticancer Res. 2020;40:689-694.
    PubMed     Abstract available


  143. YAMASHITA H, Ishida N, Hatanaka Y, Hagio K, et al
    HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence.
    Anticancer Res. 2020;40:645-652.
    PubMed     Abstract available


  144. MIMOUN C, Zeller A, Seror J, Majoulet L, et al
    A Pre-operative Score to Discriminate Fibroepithelial Lesions of the Breast: Phyllode Tumor or Fibroadenoma?
    Anticancer Res. 2020;40:1095-1100.
    PubMed     Abstract available


  145. PISTOLESE CA, Lamacchia F, Tosti D, Anemona L, et al
    Reducing the Number of Unnecessary Percutaneous Biopsies: The Role of Second Opinion by Expert Breast Center Radiologists.
    Anticancer Res. 2020;40:939-950.
    PubMed     Abstract available


    January 2020
  146. JANSSEN S, Haus R, Schild SE, Rades D, et al
    A Simple Clinical Instrument to Predict the Survival Probability of Breast Cancer Patients Receiving Radiotherapy for Bone Metastases.
    Anticancer Res. 2020;40:367-371.
    PubMed     Abstract available


  147. TAYEH S, Gera R, Perry N, Michell M, et al
    The Use of Magnetic Seeds and Radiofrequency Identifier Tags in Breast Surgery for Non-palpable Lesions.
    Anticancer Res. 2020;40:315-321.
    PubMed     Abstract available


  148. BUONOMO OC, Grasso A, Pistolese CA, Anemona L, et al
    Evaluation of Concordance Between Histopathological, Radiological and Biomolecular Variables in Breast Cancer Neoadjuvant Treatment.
    Anticancer Res. 2020;40:281-286.
    PubMed     Abstract available


  149. PEREIRA MC, Mohammed R, VAN Otterlo WAL, DE Koning CB, et al
    In Vitro Analysis of the Combinatory Effects of Novel Aminonaphthoquinone Derivatives and Curcumin on Breast Cancer Progression.
    Anticancer Res. 2020;40:229-238.
    PubMed     Abstract available


  150. MOTOMURA H, Nozaki Y, Onaga C, Ozaki A, et al
    High Expression of c-Met, PKClambda and ALDH1A3 Predicts a Poor Prognosis in Late-stage Breast Cancer.
    Anticancer Res. 2020;40:35-52.
    PubMed     Abstract available


  151. STEED KL, Jordan HR, Tollefsbol TO
    SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2.
    Anticancer Res. 2020;40:9-26.
    PubMed     Abstract available


    December 2019
  152. OTA D, Akatsuka S, Nishi T, Kato T, et al
    Phase I Study of Combination Therapy With Weekly Nanoparticle Albumin-bound Paclitaxel and Cyclophosphamide in Metastatic Breast Cancer Patients.
    Anticancer Res. 2019;39:6903-6907.
    PubMed     Abstract available


  153. BOCZAR D, Restrepo DJ, Sisti A, Huayllani MT, et al
    Influence of Facility Characteristics on Access to Breast Reconstruction: A 12-Year National Cancer Database Analysis.
    Anticancer Res. 2019;39:6881-6885.
    PubMed     Abstract available


    November 2019
  154. WERNER EM, Eggert MC, Bohnet S, Rades D, et al
    Prevalence and Characteristics of Pneumonitis Following Irradiation of Breast Cancer.
    Anticancer Res. 2019;39:6355-6358.
    PubMed     Abstract available


  155. HO ML, Kuo WK, Chu LJ, Yeh IH, et al
    N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies.
    Anticancer Res. 2019;39:6317-6324.
    PubMed     Abstract available


  156. MIYAKE T, Shimazu K, Tanei T, Naoi Y, et al
    Hookwire-guided Sentinel Lymph Node Biopsy Using Contrast-enhanced Ultrasonography Followed by a One-step Nucleic Acid Amplification (OSNA) Assay for Breast Cancer.
    Anticancer Res. 2019;39:6183-6192.
    PubMed     Abstract available


  157. RAMDANI LH, Talhi O, Decombat C, Vermerie M, et al
    Bis(4-hydroxy-2H-chromen-2-one) Coumarin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Aromatase Inhibition.
    Anticancer Res. 2019;39:6107-6114.
    PubMed     Abstract available


  158. JAASKELAINEN A, Jukkola A, Haapasaari KM, Auvinen P, et al
    Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer.
    Anticancer Res. 2019;39:5879-5890.
    PubMed     Abstract available


  159. CANITROT E, Diorio C
    Dairy Food Consumption and Mammographic Breast Density: The Role of Fat.
    Anticancer Res. 2019;39:6197-6208.
    PubMed     Abstract available


    October 2019
  160. RESTREPO DJ, Boczar D, Huayllani MT, Sisti A, et al
    Survival Disparities in Male Patients With Breast Cancer.
    Anticancer Res. 2019;39:5669-5674.
    PubMed     Abstract available


  161. OZAWA H, Sata A, Fukui R, Bun A, et al
    A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
    Anticancer Res. 2019;39:5653-5662.
    PubMed     Abstract available


  162. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Clinical Evaluation of Dynamic Monitoring of Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratios in Primary Endocrine Therapy for Advanced Breast Cancer.
    Anticancer Res. 2019;39:5581-5588.
    PubMed     Abstract available


  163. MORGAN S, Amemiya Y, Slodkowska E, Lu FI, et al
    Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients.
    Anticancer Res. 2019;39:5345-5352.
    PubMed     Abstract available


  164. DAMASKOS C, Garmpi A, Nikolettos K, Vavourakis M, et al
    Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
    Anticancer Res. 2019;39:5285-5296.
    PubMed     Abstract available


  165. CANALE ML, Camerini A, Huqi A, Lilli A, et al
    Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity.
    Anticancer Res. 2019;39:5741-5745.
    PubMed     Abstract available


  166. SUSINI T, Renda I, Giani M, Vallario A, et al
    Changing Trends in Mastectomy and Breast Reconstruction. Analysis of a Single-institution Experience Between 2004-2016.
    Anticancer Res. 2019;39:5709-5714.
    PubMed     Abstract available


  167. WOO HY, DO SI, Kim SH, Song SY, et al
    Promoter Methylation Down-regulates B-cell Translocation Gene 1 Expression in Breast Carcinoma.
    Anticancer Res. 2019;39:5361-5367.
    PubMed     Abstract available


    September 2019
  168. GOMES I, Aguiar P, Miranda A, Nunes C, et al
    Overall Survival of Patients With Locoregional and Metastatic Breast Cancer: Is the Influence of Baseline Characteristics the Same?
    Anticancer Res. 2019;39:5135-5142.
    PubMed     Abstract available


  169. INOUE N, Li W, Fujimoto Y, Matsushita Y, et al
    High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer.
    Anticancer Res. 2019;39:5009-5018.
    PubMed     Abstract available


  170. LEWIN NL, Luetragoon T, Shamoun L, Oliva D, et al
    The Influence of Adjuvant Radiotherapy and Single Nucleotide Polymorphisms on Circulating Immune Response Cell Numbers and Phenotypes of Patients With Breast Cancer.
    Anticancer Res. 2019;39:4957-4963.
    PubMed     Abstract available


  171. RESTREPO DJ, Sisti A, Boczar D, Huayllani MT, et al
    Characteristics of Breast Cancer Patients Who Refuse Surgery.
    Anticancer Res. 2019;39:4941-4945.
    PubMed     Abstract available


  172. NASIOUDIS D, Wilson E, Mastroyannis SA, Sisti G, et al
    Increased Risk of Breast and Uterine Cancer Among Women With Ovarian Granulosa Cell Tumors.
    Anticancer Res. 2019;39:4971-4975.
    PubMed     Abstract available


  173. HUNAKOVA L, Horvathova E, Gronesova P, Bobal P, et al
    Triorganotin Isothiocyanates Affect Migration and Immune Check-point Receptors in Human Triple-negative Breast Carcinoma MDA-MB-231 Cells.
    Anticancer Res. 2019;39:4845-4851.
    PubMed     Abstract available


    August 2019
  174. CHO O, Chun M, Kim SW, Jung YS, et al
    Lymphopenia as a Potential Predictor of Ipsilateral Breast Tumor Recurrence in Early Breast Cancer.
    Anticancer Res. 2019;39:4467-4474.
    PubMed     Abstract available


  175. SEDLOEV T, Vlahova A, Usheva S, Vasileva-Slaveva M, et al
    Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.
    Anticancer Res. 2019;39:4393-4398.
    PubMed     Abstract available


  176. TUOHINEN SS, Skytta T, Huhtala H, Virtanen V, et al
    Left Ventricular Speckle Tracking Echocardiography Changes Among Early-stage Breast Cancer Patients Three Years After Radiotherapy.
    Anticancer Res. 2019;39:4227-4236.
    PubMed     Abstract available


  177. KOLBERG HC, Uhl V, Massarut S, Holmes D, et al
    Targeted Intraoperative Radiotherapy During Breast-conserving Surgery for Breast Cancer in Patients After Implant Augmentation.
    Anticancer Res. 2019;39:4215-4218.
    PubMed     Abstract available


  178. MENDONCA P, Darwish AG, Tsolova V, El-Sharkawy I, et al
    The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells.
    Anticancer Res. 2019;39:4043-4053.
    PubMed     Abstract available


  179. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
    Anticancer Res. 2019;39:4031-4041.
    PubMed     Abstract available


  180. NISHIMURA M, Onoe T, Sakai H, Arase M, et al
    Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.
    Anticancer Res. 2019;39:4379-4383.
    PubMed     Abstract available


  181. HAYASHI M, Nakazawa K, Hasegawa Y, Horiguchi J, et al
    Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.
    Anticancer Res. 2019;39:4305-4314.
    PubMed     Abstract available


  182. YUE CH, Liu JY, Chi CS, Hu CW, et al
    Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERalpha Signaling Pathway in High-level MZF1-expressing TNBC cells.
    Anticancer Res. 2019;39:4149-4164.
    PubMed     Abstract available


    July 2019
  183. SHIMADA K, Ishikawa T, Yamada A, Sugae S, et al
    Matrix-producing Carcinoma as an Aggressive Triple-negative Breast Cancer: Clinicopathological Features and Response to Neoadjuvant Chemotherapy.
    Anticancer Res. 2019;39:3863-3869.
    PubMed     Abstract available


  184. CSONKA A, Kincses A, Nove M, Vadas Z, et al
    Selenoesters and Selenoanhydrides as Novel Agents Against Resistant Breast Cancer.
    Anticancer Res. 2019;39:3777-3783.
    PubMed     Abstract available


  185. STRAVODIMOU A, Voutsadakis IA
    A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer.
    Anticancer Res. 2019;39:3295-3301.
    PubMed     Abstract available


    June 2019
  186. SUSINI T, Carriero C, Tani F, Mattioli G, et al
    Day Surgery Management of Early Breast Cancer: Feasibility and Psychological Outcomes.
    Anticancer Res. 2019;39:3141-3146.
    PubMed     Abstract available


  187. PARK JH, Lee HJ, Lee SB, Ahn JH, et al
    Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer.
    Anticancer Res. 2019;39:3111-3119.
    PubMed     Abstract available


  188. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Prognostic Value of Quality of Life in Endocrine Therapy for Elderly Patients With Breast Cancer: A Retrospective Study.
    Anticancer Res. 2019;39:2941-2950.
    PubMed     Abstract available


  189. HERO T, Buhler H, Kouam PN, Priesch-Grzeszowiak B, et al
    The Triple-negative Breast Cancer Cell Line MDA-MB 231 Is Specifically Inhibited by the Ionophore Salinomycin.
    Anticancer Res. 2019;39:2821-2827.
    PubMed     Abstract available


  190. RESTREPO DJ, Boczar D, Huayllani MT, Sisti A, et al
    Influence of Race, Income, Insurance, and Education on the Rate of Breast Reconstruction.
    Anticancer Res. 2019;39:2969-2973.
    PubMed     Abstract available


  191. LINDBLOM EK, Hui S, Brooks J, Dasu A, et al
    Radiation-induced Vascular Damage and the Impact on the Treatment Outcome of Stereotactic Body Radiotherapy.
    Anticancer Res. 2019;39:2721-2727.
    PubMed     Abstract available


    May 2019
  192. VOGEL C, Malter W, Morgenstern B, Ludwig S, et al
    The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer.
    Anticancer Res. 2019;39:2647-2659.
    PubMed     Abstract available


  193. TANAKA Y, Kosaka Y, Waraya M, Yokota K, et al
    Differential Prognostic Relevance of Promoter DNA Methylation of CDO1 and HOPX in Primary Breast Cancer.
    Anticancer Res. 2019;39:2289-2298.
    PubMed     Abstract available


  194. ATIYA HI, Dvorkin-Gheva A, Hassell J, Patel S, et al
    Intraductal Adaptation of the 4T1 Mouse Model of Breast Cancer Reveals Effects of the Epithelial Microenvironment on Tumor Progression and Metastasis.
    Anticancer Res. 2019;39:2277-2287.
    PubMed     Abstract available


  195. EICHLER C, Schulz C, Thangarajah F, Malter W, et al
    A Retrospective Head-to-head Comparison Between TiLoop Bra/TiMesh(R) and Seragyn(R) in 320 Cases of Reconstructive Breast Surgery.
    Anticancer Res. 2019;39:2599-2605.
    PubMed     Abstract available


  196. RUSAK A, Jablonska K, Piotrowska A, Grzegrzolka J, et al
    Correlation of Expression of CHI3L1 and Nogo-A and their Role in Angiogenesis in Invasive Ductal Breast Carcinoma.
    Anticancer Res. 2019;39:2341-2350.
    PubMed     Abstract available


    April 2019
  197. TOKUNAGA S, Takashima T, Kashiwagi S, Noda S, et al
    Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial.
    Anticancer Res. 2019;39:2053-2059.
    PubMed     Abstract available


  198. LEE SM, Lee KW, Kim MA, Song YS, et al
    Serial Texture Analyses on ADC Maps for Evaluation of Antiangiogenic Therapy in Rat Breast Cancer.
    Anticancer Res. 2019;39:1875-1882.
    PubMed     Abstract available


  199. ALVES LN, Missailidis S, Lage CAS, DE Almeida CEB, et al
    Anti-MUC1 Aptamer as Carrier Tool of the Potential Radiosensitizer Phenanthroline in MCF-7 Breast Cancer 1,10 Cells.
    Anticancer Res. 2019;39:1859-1867.
    PubMed     Abstract available


  200. MEGO M, Karaba M, Minarik G, Benca J, et al
    Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
    Anticancer Res. 2019;39:1829-1837.
    PubMed     Abstract available


  201. PINELLI A, Ferrario P, Trivulzio S
    Preliminary Observation on the Cytotoxic Activity of New Chlorophyllin Derivative RCD on Human Tumour Cell Lines In Vitro.
    Anticancer Res. 2019;39:1807-1812.
    PubMed     Abstract available


  202. GKANTAIFI A, Papadopoulos C, Spyropoulou D, Toumpourleka M, et al
    Breast Radiotherapy and Early Adverse Cardiac Effects. The Role of Serum Biomarkers and Strain Echocardiography.
    Anticancer Res. 2019;39:1667-1673.
    PubMed     Abstract available


    March 2019
  203. SHIMAZU K, Miyake T, Okuno J, Naoi Y, et al
    One-step Nucleic Acid Amplification Can Identify Sentinel Node-negative Breast Cancer Patients With Excellent Prognosis.
    Anticancer Res. 2019;39:1447-1454.
    PubMed     Abstract available


  204. LEWIN NL, Luetragoon T, Andersson BA, Oliva D, et al
    The Influence of Single Nucleotide Polymorphisms and Adjuvant Radiotherapy on Systemic Inflammatory Proteins, Chemokines and Cytokines of Patients With Breast Cancer.
    Anticancer Res. 2019;39:1287-1292.
    PubMed     Abstract available


  205. VELLANKI SH, Cruz RGB, Richards CE, Smith YE, et al
    Antibiotic Tetrocarcin-A Down-regulates JAM-A, IAPs and Induces Apoptosis in Triple-negative Breast Cancer Models.
    Anticancer Res. 2019;39:1197-1204.
    PubMed     Abstract available


  206. HANSEN HC, Janssen S, Thieme C, Perlov A, et al
    Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses.
    Anticancer Res. 2019;39:1343-1346.
    PubMed     Abstract available


  207. REZNICZEK GA, Grunwald C, Hilal Z, Scheich J, et al
    ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).
    Anticancer Res. 2019;39:1267-1273.
    PubMed     Abstract available


  208. PAPAIOANNOU E, Sakellakis M, Melachrinou M, Tzoracoleftherakis E, et al
    A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis.
    Anticancer Res. 2019;39:1217-1232.
    PubMed     Abstract available


    February 2019
  209. SONNENBLICK A, Bailey A, Uziely B, Untch M, et al
    Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.
    Anticancer Res. 2019;39:797-802.
    PubMed     Abstract available


  210. LEE SJ, Jeong JH, Lee IH, Lee J, et al
    Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.
    Anticancer Res. 2019;39:751-758.
    PubMed     Abstract available


  211. SEKI T, Liu J, Brutkiewicz RR, Tsuji M, et al
    A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.
    Anticancer Res. 2019;39:549-555.
    PubMed     Abstract available


  212. MIYAKE T, Kim SJ, Shimoda M, Kagara N, et al
    Diagnostic Utility of Third-Look, Contrast-Enhanced Sonography Followed by Needle Biopsy for MRI, But Not Ultrasonography Breast Lesions.
    Anticancer Res. 2019;39:915-921.
    PubMed     Abstract available


  213. KOSTRZEWA T, Przychodzen P, Gorska-Ponikowska M, Kuban-Jankowska A, et al
    Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential.
    Anticancer Res. 2019;39:745-749.
    PubMed     Abstract available


    January 2019
  214. ROINE E, Farkkila N, Sintonen H, Taari K, et al
    Costs in Different States of Breast Cancer.
    Anticancer Res. 2019;39:353-359.
    PubMed     Abstract available


  215. TAKALA L, Barlund M, Kellokumpu-Lehtinen PL, Pirkko L, et al
    Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer.
    Anticancer Res. 2019;39:279-283.
    PubMed     Abstract available


  216. FREGATTI P, Gipponi M, Depaoli F, Murelli F, et al
    No Ink on Ductal Carcinoma In Situ: A Single Centre Experience.
    Anticancer Res. 2019;39:459-466.
    PubMed     Abstract available


  217. BAE GE, Yoon N, Cho EY, Kim HS, et al
    Clinicopathological and Molecular Characteristics of Mammary Adenoid Cystic Carcinoma With Adipocytic Differentiation With Emphasis on the Identification of a Novel BRAF Mutation.
    Anticancer Res. 2019;39:369-374.
    PubMed     Abstract available


  218. EICHLER C, Fromme J, Thangarajah F, Puppe J, et al
    Gene-expression Profiling - A Decision Impact Analysis: Decision Dependency on Oncotype DX(R) as a Function of Oncological Work Experience in 117 Cases.
    Anticancer Res. 2019;39:297-303.
    PubMed     Abstract available


    December 2018
  219. RADES D, Panzner A, Janssen S, Dunst J, et al
    Outcomes After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients with Oligo-metastatic Breast Cancer.
    Anticancer Res. 2018;38:6897-6903.
    PubMed     Abstract available


  220. MANOUCHEHRI JM, Kalafatis M
    Ursolic Acid Promotes the Sensitization of rhTRAIL-resistant Triple-negative Breast Cancer.
    Anticancer Res. 2018;38:6789-6795.
    PubMed     Abstract available


  221. OLIVA D, Nilsson M, Strandeus M, Andersson BA, et al
    Individual Genetic Variation Might Predict Acute Skin Reactions in Women Undergoing Adjuvant Breast Cancer Radiotherapy.
    Anticancer Res. 2018;38:6763-6770.
    PubMed     Abstract available


  222. ORSARIA P, Chiaravalloti A, Caredda E, Marchese PV, et al
    Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
    Anticancer Res. 2018;38:6639-6652.
    PubMed     Abstract available


  223. GERA R, Tayeh S, Chehade HE, Mokbel K, et al
    Does Transdermal Testosterone Increase the Risk of Developing Breast Cancer? A Systematic Review.
    Anticancer Res. 2018;38:6615-6620.
    PubMed     Abstract available


  224. SHERBET GV, Woo WL, Dlay S
    Application of Artificial Intelligence-based Technology in Cancer Management: A Commentary on the Deployment of Artificial Neural Networks.
    Anticancer Res. 2018;38:6607-6613.
    PubMed     Abstract available


    November 2018
  225. STEFANOU D, Kokkali S, Tripodaki ES, Drizou M, et al
    Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:6565-6569.
    PubMed     Abstract available


  226. SAKAGUCHI M, Maebayashi T, Aizawa T, Ishibashi N, et al
    Whole-brain Radiation Therapy for Breast Cancer Patients with Dural Metastasis Without Concomitant Brain Metastasis and Leptomeningeal Metastasis.
    Anticancer Res. 2018;38:6405-6411.
    PubMed     Abstract available


  227. FU S, Lin J
    Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
    Anticancer Res. 2018;38:6271-6279.
    PubMed     Abstract available


  228. DU X, Klaschik K, Mallmann P, Isachenko E, et al
    An Experimental Model of Breast Cancer Cells: Informative Protocol for In Vitro Culture.
    Anticancer Res. 2018;38:6237-6245.
    PubMed     Abstract available


  229. SHI H, Liu J, Tu Y, Freter CE, et al
    Oolong Tea Extract Induces DNA Damage and Cleavage and Inhibits Breast Cancer Cell Growth and Tumorigenesis.
    Anticancer Res. 2018;38:6217-6223.
    PubMed     Abstract available


  230. TOROPOV AA, Toropova AP
    Predicting Cytotoxicity of 2-Phenylindole Derivatives Against Breast Cancer Cells Using Index of Ideality of Correlation.
    Anticancer Res. 2018;38:6189-6194.
    PubMed     Abstract available


  231. MUSA MA, Badisa VLD, Latinwo LM, Ntantie E, et al
    7,8-Dihydroxy-3-arylcoumarin Induces Cell Death Through S-Phase Arrest in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2018;38:6091-6098.
    PubMed     Abstract available


  232. LUCCHETTI J, Formica V, Giuliano G, Coletta D, et al
    Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia.
    Anticancer Res. 2018;38:6561-6564.
    PubMed     Abstract available


  233. KORDONI M, Rigakos G, Kim YHM, Kaklamanis L, et al
    Atypical Femoral Fractures (AFF) from Bone Remodeling Agents in Patients with Cancer.
    Anticancer Res. 2018;38:6439-6444.
    PubMed     Abstract available


    October 2018
  234. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
    Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Anticancer Res. 2018;38:6023-6026.
    PubMed     Abstract available


  235. KONDO Y, Fukuyama T, Yamamura R, Futawatari N, et al
    Detection of KK-LC-1 Protein, a Cancer/Testis Antigen, in Patients with Breast Cancer.
    Anticancer Res. 2018;38:5923-5928.
    PubMed     Abstract available


  236. DUTTA D, Russell C, Kim J, Chandra S, et al
    Differential Mobility of Breast Cancer Cells and Normal Breast Epithelial Cells Under DC Electrophoresis and Electroosmosis.
    Anticancer Res. 2018;38:5733-5738.
    PubMed     Abstract available


  237. ICHIHARA H, Okumura M, Tsujimura K, Matsumoto Y, et al
    Theranostics with Hybrid Liposomes in an Orthotopic Graft Model Mice of Breast Cancer.
    Anticancer Res. 2018;38:5645-5654.
    PubMed     Abstract available


  238. FREEMAN J, Crowley PD, Foley AG, Gallagher HC, et al
    Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery.
    Anticancer Res. 2018;38:5599-5606.
    PubMed     Abstract available


    September 2018
  239. BONZANO E, Belgioia L, Fregatti P, Friedman D, et al
    Tumor Size-driven Dose of Intraoperative Radiotherapy for Breast Cancer: 18 Gy Versus 21 Gy.
    Anticancer Res. 2018;38:5475-5479.
    PubMed     Abstract available


  240. NAKATSUKASA K, Ouchi Y, Sakaguchi K, Goto M, et al
    Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
    Anticancer Res. 2018;38:5459-5463.
    PubMed     Abstract available


  241. JOO JH, Kim SS, Son BH, DO Ahn S, et al
    Evaluation of the Prognostic Stage in the 8th Edition of the American Joint Committee on Cancer in Patients with Breast Cancer and Internal Mammary Lymph Node Metastasis.
    Anticancer Res. 2018;38:5357-5361.
    PubMed     Abstract available


  242. ZHOU M, Peddi P, Chu QD
    Radiation Therapy for Positive Surgical Margins in Women >/=70 Years with Stage I, Estrogen Receptor-positive Breast Cancer.
    Anticancer Res. 2018;38:5253-5260.
    PubMed     Abstract available


  243. WILHELM CA, Clor ZJ, Kelts JL
    Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:5043-5048.
    PubMed     Abstract available


  244. LEBLANC N, Harquail J, Crapoulet N, Ouellette RJ, et al
    Pax-5 Inhibits Breast Cancer Proliferation Through MiR-215 Up-regulation.
    Anticancer Res. 2018;38:5013-5026.
    PubMed     Abstract available


  245. PARK HL, Pyo YC, Kim KY, Park JS, et al
    Recurrence Rates and Characteristics of Phyllodes Tumors Diagnosed by Ultrasound-guided Vacuum-assisted Breast Biopsy (VABB).
    Anticancer Res. 2018;38:5481-5487.
    PubMed     Abstract available


    August 2018
  246. FUJII T, Yanai K, Tokuda S, Nakazawa Y, et al
    Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer.
    Anticancer Res. 2018;38:4927-4931.
    PubMed     Abstract available


  247. ROSSI L, Biagioni C, McCartney A, Moretti E, et al
    Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.
    Anticancer Res. 2018;38:4839-4845.
    PubMed     Abstract available


  248. MOKBEL K, Wazir U, Wazir A, Kasem A, et al
    The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER(+)/HER2(-) Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic Index.
    Anticancer Res. 2018;38:4747-4752.
    PubMed     Abstract available


  249. FERRONI P, Roselli M, Buonomo OC, Spila A, et al
    Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer.
    Anticancer Res. 2018;38:4705-4712.
    PubMed     Abstract available


  250. WINSKA P, Skierka K, Lukowska-Chojnacka E, Koronkiewicz M, et al
    Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
    Anticancer Res. 2018;38:4617-4627.
    PubMed     Abstract available


  251. YEH MH, Tzeng YJ, Fu TY, You JJ, et al
    Extracellular Matrix-receptor Interaction Signaling Genes Associated with Inferior Breast Cancer Survival.
    Anticancer Res. 2018;38:4593-4605.
    PubMed     Abstract available


  252. RABACOW APM, Meza A, DE Oliveira EJT, DE David N, et al
    Evaluation of the Antitumor Potential of the Resorcinolic Lipid 3-Heptyl-3,4,6-trimethoxy-3H-isobenzofuran-1-one in Breast Cancer Cells.
    Anticancer Res. 2018;38:4565-4576.
    PubMed     Abstract available


  253. KENAN ES, Friger M, Shochat-Bigon D, Schayek H, et al
    Accuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in Israel.
    Anticancer Res. 2018;38:4557-4563.
    PubMed     Abstract available


  254. MASUDA T, Shinden Y, Noda M, Ueo H, et al
    Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer.
    Anticancer Res. 2018;38:4515-4523.
    PubMed     Abstract available


  255. BOMMAREDDY A, Knapp AWK, Nemeth A, Steigerwalt J, et al
    Alpha-Santalol, a Component of Sandalwood Oil Inhibits Migration of Breast Cancer Cells by Targeting the beta-catenin Pathway.
    Anticancer Res. 2018;38:4475-4480.
    PubMed     Abstract available


  256. HUNKE M, Martinez W, Kashyap A, Bokoskie T, et al
    Antineoplastic Actions of Cinnamic Acids and Their Dimers in Breast Cancer Cells: A Comparative Study.
    Anticancer Res. 2018;38:4469-4474.
    PubMed     Abstract available


  257. ANDING AL, Jones JD, Newton MA, Curley RW Jr, et al
    4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
    Anticancer Res. 2018;38:4403-4416.
    PubMed     Abstract available


  258. CAZZANIGA M, Bonanni B
    Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?
    Anticancer Res. 2018;38:4393-4402.
    PubMed     Abstract available


  259. SPRAVE T, Verma V, Forster R, Schlampp I, et al
    Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial.
    Anticancer Res. 2018;38:4961-4968.
    PubMed     Abstract available


  260. HUANG FJ, Hung CC, Chang CW, Chao JH, et al
    Evaluation of Injectable Chitosan-based Co-cross-linking Hydrogel for Local Delivery of (188)Re-LIPO-DOX to Breast-tumor-bearing Mouse Model.
    Anticancer Res. 2018;38:4651-4659.
    PubMed     Abstract available


  261. EMMANUEL N, Lofgren KA, Peterson EA, Meier DR, et al
    Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells.
    Anticancer Res. 2018;38:4435-4441.
    PubMed     Abstract available


    July 2018
  262. MORI H, Kubo M, Kai M, Kurata K, et al
    Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.
    Anticancer Res. 2018;38:4381-4386.
    PubMed     Abstract available


  263. TANAKA T, Uchida H
    Inhibition of Survivin by Adenovirus Vector Enhanced Paclitaxel-induced Apoptosis in Breast Cancer Cells.
    Anticancer Res. 2018;38:4281-4288.
    PubMed     Abstract available


  264. KUBO M, Umebayashi M, Kurata K, Mori H, et al
    Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:4273-4279.
    PubMed     Abstract available


  265. SAKAGUCHI K, Nakatsukasa K, Koyama H, Kato M, et al
    Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:4073-4081.
    PubMed     Abstract available


  266. CHIANG KC, Yeh CN, Yeh TS, Juang HH, et al
    MART-10, a 1alpha,25(OH)2D3 Analog, Potently Represses Metastasis of ER(+) Breast Cancer Cells with VEGF-A Overexpression.
    Anticancer Res. 2018;38:3879-3887.
    PubMed     Abstract available


  267. TORATA N, Kubo M, Miura D, Ohuchida K, et al
    Visualizing Energy Charge in Breast Carcinoma Tissues by MALDI Mass-spectrometry Imaging Profiles of Low-molecular-weight Metabolites.
    Anticancer Res. 2018;38:4267-4272.
    PubMed     Abstract available


  268. FERDOVA E, Baxa J, Narsanska A, Hes O, et al
    Low-dose High-resolution (18)F-FDG-PET/CT Using Time-of-flight and Point-spread Function Reconstructions: A Role in the Detection of Breast Carcinoma Axillary Lymph Node Metastases.
    Anticancer Res. 2018;38:4145-4148.
    PubMed     Abstract available


  269. GRUBER I, Henzel M, Schonfisch B, Stabler A, et al
    Prediction of Non-sentinel Lymph Node Metastases After Positive Sentinel Lymph Nodes Using Nomograms.
    Anticancer Res. 2018;38:4047-4056.
    PubMed     Abstract available


    June 2018
  270. MALTER W, Hellmich M, Badian M, Kirn V, et al
    Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
    Anticancer Res. 2018;38:3657-3662.
    PubMed     Abstract available


  271. TRESKA V, Topolcan O, Zoubkova V, Treskova I, et al
    Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases.
    Anticancer Res. 2018;38:3647-3652.
    PubMed     Abstract available


  272. LI J, Zhang J, Jin L, Deng H, et al
    Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway.
    Anticancer Res. 2018;38:3427-3434.
    PubMed     Abstract available


  273. CHOE MH, Kim J, Ahn J, Hwang SG, et al
    Centrosome Clustering Is a Tumor-selective Target for the Improvement of Radiotherapy in Breast Cancer Cells.
    Anticancer Res. 2018;38:3393-3400.
    PubMed     Abstract available


  274. DANDAMUDI A, Tommie J, Nommsen-Rivers L, Couch S, et al
    Dietary Patterns and Breast Cancer Risk: A Systematic Review.
    Anticancer Res. 2018;38:3209-3222.
    PubMed     Abstract available


  275. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Abstract available


  276. RUSAK A, Jablonska K, Piotrowska A, Grzegrzolka J, et al
    The Role of CHI3L1 Expression in Angiogenesis in Invasive Ductal Breast Carcinoma.
    Anticancer Res. 2018;38:3357-3366.
    PubMed     Abstract available


    May 2018
  277. CHANG J, Charalel R, Noda C, Ramaswamy R, et al
    Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization.
    Anticancer Res. 2018;38:3063-3068.
    PubMed     Abstract available


  278. LUMACHI F, Basso SMM, Camozzi V, Spaziante R, et al
    Bone Mineral Density as a Potential Predictive Factor for Luminal-type Breast Cancer in Postmenopausal Women.
    Anticancer Res. 2018;38:3049-3054.
    PubMed     Abstract available


  279. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
    Anticancer Res. 2018;38:2929-2938.
    PubMed     Abstract available


  280. KORONOWICZ AA, Drozdowska M, Banks P, Piasna-Slupecka E, et al
    Fatty Acids of CLA-enriched Egg Yolks Can Induce Mitochondrial Pathway of Apoptosis in MCF-7 Breast Cancer Cells.
    Anticancer Res. 2018;38:2861-2870.
    PubMed     Abstract available


  281. MINAFRA L, Bravata V, Cammarata FP, Russo G, et al
    Radiation Gene-expression Signatures in Primary Breast Cancer Cells.
    Anticancer Res. 2018;38:2707-2715.
    PubMed     Abstract available


  282. REINHARDT A, Liu H, Ma Y, Zhou Y, et al
    Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.
    Anticancer Res. 2018;38:2669-2682.
    PubMed     Abstract available


  283. TUNGSUKRUTHAI S, Petpiroon N, Chanvorachote P
    Molecular Mechanisms of Breast Cancer Metastasis and Potential Anti-metastatic Compounds.
    Anticancer Res. 2018;38:2607-2618.
    PubMed     Abstract available


  284. LEHMANN-CHE J, Miquel C, Wong J, Callens C, et al
    First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.
    Anticancer Res. 2018;38:2909-2914.
    PubMed     Abstract available


  285. LIU LC, Wu YC, Kuo SC, Ho CT, et al
    2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells.
    Anticancer Res. 2018;38:2849-2859.
    PubMed     Abstract available


  286. TATARA T, Mukohara T, Tanaka R, Shimono Y, et al
    3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.
    Anticancer Res. 2018;38:2831-2839.
    PubMed     Abstract available


  287. OKARVI SM, Aljammaz I
    Preparation and In Vitro and In Vivo Characterization of the Tumor-specific Antigen-derived Peptide as a Potential Candidate for Targeting Human Epidermal Growth Factor Receptor 2-positive Breast Carcinomas.
    Anticancer Res. 2018;38:2823-2830.
    PubMed     Abstract available


    April 2018
  288. INOUE Y, Yamashita N, Ueo H, Tanaka K, et al
    The Clinical Usefulness of the LigaSure Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer.
    Anticancer Res. 2018;38:2359-2362.
    PubMed     Abstract available


  289. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Anticancer Res. 2018;38:2311-2321.
    PubMed     Abstract available


  290. TAKADA K, Kashiwagi S, Goto W, Asano Y, et al
    Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:2285-2294.
    PubMed     Abstract available


  291. TUOHINEN SS, Keski-Pukkila K, Skytta T, Huhtala H, et al
    Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer.
    Anticancer Res. 2018;38:2207-2215.
    PubMed     Abstract available


  292. HSIAO CL, Liu LC, Shih TC, Chuang CL, et al
    The Association of Matrix Metalloproteinase-8 Promoter Genotypes in Breast Cancer.
    Anticancer Res. 2018;38:2181-2185.
    PubMed     Abstract available


  293. ORSARIA P, Caredda E, Genova F, Materazzo M, et al
    Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
    Anticancer Res. 2018;38:2109-2117.
    PubMed     Abstract available


  294. UEMATSU N, Zhao Y, Kiyomi A, Yuan BO, et al
    Chemo-sensitivity of Two-dimensional Monolayer and Three-dimensional Spheroid of Breast Cancer MCF-7 Cells to Daunorubicin, Docetaxel, and Arsenic Disulfide.
    Anticancer Res. 2018;38:2101-2108.
    PubMed     Abstract available


  295. JUZENIENE A, Bernoulli J, Suominen M, Halleen J, et al
    Antitumor Activity of Novel Bone-seeking, alpha-emitting (224)Ra-solution in a Breast Cancer Skeletal Metastases Model.
    Anticancer Res. 2018;38:1947-1955.
    PubMed     Abstract available


  296. PARK HL, Kim KY, Park JS, Shin JE, et al
    Clinicopathological Analysis of Ultrasound-guided Vacuum-assisted Breast Biopsy for the Diagnosis and Treatment of Breast Disease.
    Anticancer Res. 2018;38:2455-2462.
    PubMed     Abstract available


  297. YU JK, Yue CH, Pan YR, Chiu YW, et al
    Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition via Down-regulation of EGFR Pathway in MDA-MB-231 cells.
    Anticancer Res. 2018;38:2127-2135.
    PubMed     Abstract available


  298. LITWIN M, Szczepanska-Buda A, Michalowska D, Grzegrzolka J, et al
    Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance in Ductal Breast Carcinoma.
    Anticancer Res. 2018;38:2021-2030.
    PubMed     Abstract available


  299. NIEMIEC J, Adamczyk A, Harazin-Lechowska A, Ambicka A, et al
    Podoplanin-positive Cancer-associated Stromal Fibroblasts in Primary Tumor and Synchronous Lymph Node Metastases of HER2-overexpressing Breast Carcinomas.
    Anticancer Res. 2018;38:1957-1965.
    PubMed     Abstract available


    March 2018
  300. GOMES I, Miranda A, Nunes C
    Spatiotemporal Analysis of Breast Cancer Incidence: A Study in Southern Portugal Between 2005 and 2012.
    Anticancer Res. 2018;38:1797-1805.
    PubMed     Abstract available


  301. ALEXOPOULOU E, Katsila T, Tolia M, Tsoukalas N, et al
    An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients.
    Anticancer Res. 2018;38:1615-1622.
    PubMed     Abstract available


  302. FRITZ P, Dippon J, Muller S, Goletz S, et al
    Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem.
    Anticancer Res. 2018;38:1585-1593.
    PubMed     Abstract available


  303. KOI Y, Koga C, Akiyoshi S, Masuda T, et al
    Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
    Anticancer Res. 2018;38:1579-1584.
    PubMed     Abstract available


  304. DIMAS DT, Perlepe CD, Sergentanis TN, Misitzis I, et al
    The Prognostic Significance of Hsp70/Hsp90 Expression in Breast Cancer: A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:1551-1562.
    PubMed     Abstract available


  305. DE CREMOUX P, Hamy AS, Lehmann-Che J, Scott V, et al
    COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
    Anticancer Res. 2018;38:1485-1490.
    PubMed     Abstract available


  306. HA GH, Kim DY, Breuer EK, Kim CK, et al
    Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Anticancer Res. 2018;38:1303-1310.
    PubMed     Abstract available


  307. UJHELYI M, Pukancsik D, Kelemen P, Kovacs E, et al
    Barriers to Organized Mammography Screening Programs in Hungary: A Questionnaire-based Study of 3,313 Women.
    Anticancer Res. 2018;38:1727-1734.
    PubMed     Abstract available


  308. EL HAGE CHEHADE H, Mokbel K
    Is Adjuvant Endocrine Therapy Indicated for DCIS Patients After Complete Surgical Excision?
    Anticancer Res. 2018;38:1263-1266.
    PubMed     Abstract available


    February 2018
  309. FRIEDRICH M, Reichert K, Woeste A, Polack S, et al
    Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:1201-1207.
    PubMed     Abstract available


  310. FUJII T, Horiguchi J, Yanagita Y, Koibuchi Y, et al
    Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
    Anticancer Res. 2018;38:905-909.
    PubMed     Abstract available


  311. NAWA-NISHIGAKI M, Kobayashi R, Suzuki A, Hirose C, et al
    Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Anticancer Res. 2018;38:877-884.
    PubMed     Abstract available


  312. GERA R, Mokbel R, Igor I, Mokbel K, et al
    Does the Use of Hair Dyes Increase the Risk of Developing Breast Cancer? A Meta-analysis and Review of the Literature.
    Anticancer Res. 2018;38:707-716.
    PubMed     Abstract available


  313. BELKACEMI L, Atkins JL, Yang LU, Gadgil P, et al
    Phosphaplatin Anti-tumor Effect Enhanced by Liposomes Partly via an Up-regulation of PEDF in Breast Cancer.
    Anticancer Res. 2018;38:623-646.
    PubMed     Abstract available


  314. LUCZYNSKA E, Niemiec J, Heinze S, Adamczyk A, et al
    Intensity and Pattern of Enhancement on CESM: Prognostic Significance and its Relation to Expression of Podoplanin in Tumor Stroma - A Preliminary Report.
    Anticancer Res. 2018;38:1085-1095.
    PubMed     Abstract available


  315. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Abstract available


    January 2018
  316. SVOBODOVA S, Kucera R, Fiala O, Marie K, et al
    CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.
    Anticancer Res. 2018;38:465-469.
    PubMed     Abstract available


  317. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
    Anticancer Res. 2018;38:401-410.
    PubMed     Abstract available


  318. TAKASHIMA T, Kawajiri H, Nishimori T, Tei S, et al
    Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2018;38:379-383.
    PubMed     Abstract available


  319. CHAMARAUX-TRAN TN, Mathelin C, Aprahamian M, Joshi GP, et al
    Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial.
    Anticancer Res. 2018;38:95-105.
    PubMed     Abstract available


  320. JARDEL P, Vignot S, Cutuli B, Creisson A, et al
    Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review.
    Anticancer Res. 2018;38:23-31.
    PubMed     Abstract available


    December 2017
  321. PESSINA F, Navarria P, Cozzi L, Franceschini D, et al
    Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis.
    Anticancer Res. 2017;37:7057-7062.
    PubMed     Abstract available


  322. YAMANOUCHI K, Kuba S, Sakimura C, Morita M, et al
    The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer.
    Anticancer Res. 2017;37:6947-6951.
    PubMed     Abstract available


  323. MOKBEL K, Wazir U, El Hage Chehade H, Manson A, et al
    A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer.
    Anticancer Res. 2017;37:6863-6869.
    PubMed     Abstract available


  324. NIMEUS E, Folkesson E, Nodin B, Hartman L, et al
    Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
    Anticancer Res. 2017;37:6845-6853.
    PubMed     Abstract available


  325. AULA H, Skytta T, Tuohinen S, Luukkaala T, et al
    Adjuvant Breast Cancer Treatments Induce Changes in Homoarginine Level - A Prospective Observational Study.
    Anticancer Res. 2017;37:6815-6824.
    PubMed     Abstract available


  326. PEREIRA MC, Mohammed R, VAN Otterlo WAL, DE Koning CB, et al
    Evaluation of the Effects of Aminonaphthoquinone Derivatives in Combination with Curcumin Against ER-positive Breast Cancer and Related Tumours.
    Anticancer Res. 2017;37:6749-6759.
    PubMed     Abstract available


  327. STOPE MB, Weiss M, Koensgen D, Popp SL, et al
    Y-box Binding Protein-1 Enhances Oncogenic Transforming Growth Factor beta Signaling in Breast Cancer Cells via Triggering Phospho-Activation of Smad2.
    Anticancer Res. 2017;37:6745-6748.
    PubMed     Abstract available


  328. MATSUI C, Takatani-Nakase T, Maeda S, Nakase I, et al
    Potential Roles of GLUT12 for Glucose Sensing and Cellular Migration in MCF-7 Human Breast Cancer Cells Under High Glucose Conditions.
    Anticancer Res. 2017;37:6715-6722.
    PubMed     Abstract available


  329. KAR A, Liu B, Gutierrez-Hartmann A
    ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2(+) Breast Cancer Cells.
    Anticancer Res. 2017;37:6583-6591.
    PubMed     Abstract available


  330. SPARTALIS E, Tsilimigras DI, Charalampoudis P, Karachaliou GS, et al
    The "Yin and Yang" of Platelet-rich Plasma in Breast Reconstruction After Mastectomy or Lumpectomy for Breast Cancer.
    Anticancer Res. 2017;37:6557-6562.
    PubMed     Abstract available


  331. MIRKA H, Tupy R, Narsanska A, Hes O, et al
    Pre-surgical Multiparametric Assessment of Breast Lesions Using 3-Tesla Magnetic Resonance.
    Anticancer Res. 2017;37:6965-6970.
    PubMed     Abstract available


  332. SAPINHO G, Alho I, Bicho M, Coelho C, et al
    Total Knockdown of LMW-PTP in MDA-MB-231 Cells Reduces Osteoclastogenesis.
    Anticancer Res. 2017;37:6671-6677.
    PubMed     Abstract available


  333. MANOUCHEHRI JM, Kalafatis M
    Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment.
    Anticancer Res. 2017;37:6593-6599.
    PubMed     Abstract available


  334. CHRISTOPOULOS PF, Vlachogiannis NI, Vogkou CT, Koutsilieris M, et al
    The Role of the Androgen Receptor Signaling in Breast Malignancies.
    Anticancer Res. 2017;37:6533-6540.
    PubMed     Abstract available


    November 2017
  335. MATSUI A, Tatibana A, Suzuki N, Hirata M, et al
    Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.
    Anticancer Res. 2017;37:6481-6488.
    PubMed     Abstract available


  336. SHEIKH IA, Jiffri EH, Kamal MA, Ashraf GM, et al
    Lactoperoxidase, an Antimicrobial Milk Protein, as a Potential Activator of Carcinogenic Heterocyclic Amines in Breast Cancer.
    Anticancer Res. 2017;37:6415-6420.
    PubMed     Abstract available


  337. SHEIKH IA, Beg MA, Yasir M
    Molecular Interactions of Carcinogenic Aromatic Amines, 4-Aminobiphenyl and 4,4'-Diaminobiphenyl, with Lactoperoxidase - Insight to Breast Cancer.
    Anticancer Res. 2017;37:6245-6249.
    PubMed     Abstract available


  338. JEON D, Kim H, Nam K, Oh S, et al
    Cytotoxic Effect of Nano-SiO2 in Human Breast Cancer Cells via Modulation of EGFR Signaling Cascades.
    Anticancer Res. 2017;37:6189-6197.
    PubMed     Abstract available


  339. WAKIMOTO R, Ono M, Takeshima M, Higuchi T, et al
    Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells.
    Anticancer Res. 2017;37:6153-6159.
    PubMed     Abstract available


  340. DU J, Sun Y, Lu YY, Lau E, et al
    Berberine and Evodiamine Act Synergistically Against Human Breast Cancer MCF-7 Cells by Inducing Cell Cycle Arrest and Apoptosis.
    Anticancer Res. 2017;37:6141-6151.
    PubMed     Abstract available


    October 2017
  341. SHOJI F, Yamashita N, Inoue Y, Kozuma Y, et al
    Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Anticancer Res. 2017;37:5871-5876.
    PubMed     Abstract available


  342. KARMAKAR MK, Samy W, Lee A, Li JW, et al
    Survival Analysis of Patients with Breast Cancer Undergoing a Modified Radical Mastectomy With or Without a Thoracic Paravertebral Block: a 5-Year Follow-up of a Randomized Controlled Trial.
    Anticancer Res. 2017;37:5813-5820.
    PubMed     Abstract available


  343. HE K, Wang X, Guan X, Yu Q, et al
    Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.
    Anticancer Res. 2017;37:5647-5653.
    PubMed     Abstract available


  344. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
    Anticancer Res. 2017;37:5623-5630.
    PubMed     Abstract available


  345. CHU QD, Zhou M, Medeiros KL, Peddi P, et al
    Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (>/=70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
    Anticancer Res. 2017;37:5585-5594.
    PubMed     Abstract available


  346. PHAM DH, Kim JS, Kim SK, Shin DJ, et al
    Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro.
    Anticancer Res. 2017;37:5507-5513.
    PubMed     Abstract available


  347. BOBIN-DUBIGEON C, Chauvin A, Brillaud-Meflah V, Boiffard F, et al
    Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity.
    Anticancer Res. 2017;37:5495-5498.
    PubMed     Abstract available


  348. CALIS IU, Cosan DT, Mutlu F
    Effects of S1P1 and S1P3 in ER+ and ER- Breast Cancer Cells.
    Anticancer Res. 2017;37:5469-5475.
    PubMed     Abstract available


  349. GIGLI S, Amabile MI, DI Pastena F, DE Luca A, et al
    Lipofilling Outcomes Mimicking Breast Cancer Recurrence: Case Report and Update of the Literature.
    Anticancer Res. 2017;37:5395-5398.
    PubMed     Abstract available


  350. HARUNA F, Lipsett A, Marignol L
    Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2017;37:5343-5353.
    PubMed     Abstract available


  351. GLASSMAN D, Hignett S, Rehman S, Linforth R, et al
    Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.
    Anticancer Res. 2017;37:5329-5341.
    PubMed     Abstract available


  352. GRZEGRZOLKA J, Wojtyra P, Biala M, Piotrowska A, et al
    Correlation Between Expression of Twist and Podoplanin in Ductal Breast Carcinoma.
    Anticancer Res. 2017;37:5485-5493.
    PubMed     Abstract available


    September 2017
  353. ISHITOBI M, Fukui R, Hashimoto Y, Kittaka N, et al
    Safety for Repeat Lumpectomy Without Radiotherapy for Ipsilateral Breast Tumor Recurrence.
    Anticancer Res. 2017;37:5293-5299.
    PubMed     Abstract available


  354. EICHLER C, Abrar S, Puppe J, Arndt M, et al
    Detection of Ductal Carcinoma In Situ by Ultrasound and Mammography: Size-dependent Inaccuracy.
    Anticancer Res. 2017;37:5065-5070.
    PubMed     Abstract available


  355. FUJII T, Yanai K, Tokuda S, Nakazawa Y, et al
    Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings.
    Anticancer Res. 2017;37:5053-5056.
    PubMed     Abstract available


  356. UEHARA S, Saito K, Asami H, Ohta Y, et al
    Role of ARHGAP24 in ADP Ribosylation Factor 6 (ARF6)-dependent Pseudopod Formation in Human Breast Carcinoma Cells.
    Anticancer Res. 2017;37:4837-4844.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: